Cargando…
A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma
Purpose: To determine the response and toxicity of docetaxel in recurrent osteosarcoma and related spindle cell tumours of bone. Patients and methods: Fourteen patients, 10 males and four females, were enrolled, median age 30.5 years (range, 17–46). Diagnosis was: conventional osteosarcoma, 12 patie...
Autores principales: | Mctiernan, Anne, Whelan, Jeremy S. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395610/ https://www.ncbi.nlm.nih.gov/pubmed/18521398 http://dx.doi.org/10.1080/13577140410001711764 |
Ejemplares similares
-
A Phase II Study of Docetaxel in Patients with Relapsed and Refractory Ewing's Tumours
por: Meyer, T., et al.
Publicado: (2003) -
A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma
por: McTiernan, Anne, et al.
Publicado: (2006) -
A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma
por: Seddon, Beatrice, et al.
Publicado: (2015) -
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
por: Adachi, I., et al.
Publicado: (1996) -
Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma
por: Peng, Pei-Jian, et al.
Publicado: (2015)